Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2008 Aug;10(8):592-602.
doi: 10.1111/j.1751-7176.2008.07802.x.

A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen

Michael E Farkouh  1 , Freek W A Verheugt, Sean Ruland, Howard Kirshner, Raban Jeger, Xavier Gitton, Gerhard Krammer, Kirstin Stricker, Peter Sallstig, Bernhard Mellein, Patrice Matchaba, James H Chesebro
Affiliations
Randomized Controlled Trial

A comparison of the blood pressure changes of lumiracoxib with those of ibuprofen and naproxen

Michael E Farkouh et al. J Clin Hypertens (Greenwich). 2008 Aug.

Abstract

The 52-week Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET) investigated the gastrointestinal and cardiovascular safety profile of lumiracoxib 400 mg once daily compared with 2 traditional nonsteroidal anti-inflammatory drugs (NSAIDs): ibuprofen 800 mg 3 times daily and naproxen 500 mg twice daily. Data from TARGET were analyzed to examine the effect of lumiracoxib compared with ibuprofen and naproxen on blood pressure (BP), incidence of de novo and aggravated hypertension, prespecified edema events, and congestive heart failure. Lumiracoxib resulted in smaller changes in BP as early as week 4. Least-squares mean change from baseline at week 4 for systolic BP was +0.57 mm Hg with lumiracoxib compared with +3.14 mm Hg with ibuprofen (P<.0001) and +0.43 with lumiracoxib compared with +1.80 mm Hg with naproxen (P<.0001). In conclusion, the use of lumiracoxib and traditional NSAIDs results in differing BP changes; these might be of clinical relevance.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Change from baseline in systolic and diastolic blood pressure at 4 weeks for (A) lumiracoxib and ibuprofen in the overall population and (B) lumiracoxib and naproxen in the overall population. aP<.0001; bP=.0058. qd indicates once daily; tid, 3 times daily; bid, twice daily.
Figure 2
Figure 2
Incidence of de novo and aggravated hypertension for (A) lumiracoxib compared with ibuprofen and (B) lumiracoxib compared with naproxen. aP<.0001; bP<.0002; cnot significant (P=.4804 for de novo hypertension; P=.1464 for aggravated hypertension). qd indicates once daily; tid, 3 times daily; bid, twice daily; HR, hazard ratio.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Woolf AD, Pfleger B. Burden of major musculoskeletal conditions. Bull World Health Organ. 2003;81(9):646–656. - PMC - PubMed
    1. Jeger RV, Greenberg JD, Ramanathan K, et al. Lumiracoxib, a highly selective COX‐2 inhibitor. Expert Review Clin Immunol. 2005;1:37–45. - PubMed
    1. Brater DC, Harris C, Redfern JS, et al. Renal effects of COX‐2‐selective inhibitors. Am J Nephrol. 2001;21:1–15. - PubMed
    1. Harris RC. Cyclooxygenase‐2 and the kidney: functional and pathophysiological implications. J Hypertens (Suppl). 2002;20(suppl 6):S3–S9. - PubMed
    1. Singh G, Miller JD, Huse DM, et al. Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol. 2003;30:714–719. - PubMed

Publication types

MeSH terms